<DOC>
	<DOCNO>NCT00356356</DOCNO>
	<brief_summary>The purpose study evaluate extend safety efficacy etanercept adult Ankylosing Spondylitis .</brief_summary>
	<brief_title>16.0040 Ankylosing Spondylitis Study</brief_title>
	<detailed_description>This multicenter , open-label extension study evaluate safety clinical benefit etanercept treatment Ankylosing Spondylitis subject previously enrol Protocol 16.0037 .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects complete 24 week study drug protocol 16.0037 qualify enroll study Other patient meet follow criterion : Negative pregnancy test Subjects agree use appropriate contraception throughout study Should able selfinject study drug someone Capable understanding protocol willing provide write informed consent Any change NSAID prednisone dose within 2 week baseline Any change hydroxychloroquine , sulfasalazine , MTX dose within 4 week baseline Use DMARDs mention , within 4 week enrollment Previous receipt aniTNF agent , etanercept Receipt investigational drug within 30 day baseline Grade 3 4 adverse event attribute etanercept recurred etanercept resume Abnormality chemistry hematology profile significant concurrent medical event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>